New York, May 24, 2026, 12:04 (EDT)
DarioHealth Corp. shares finished the week before Memorial Day holiday down 5.3%, unable to make up earlier losses despite picking up on Friday. The stock’s slide followed a new warning about cash, which offset a small recovery in revenue.
Shares of the digital health firm on Nasdaq finished Friday at $7.86, gaining 4.1% for the day. The stock was still off last Friday’s $8.30 close. Volume stayed light, with less than 5,000 shares traded in each session last week. That sort of thin trading can swing a small-cap name.
Timing is key since U.S. equity markets will be closed Monday, May 25, for Memorial Day. So DRIO and other Nasdaq stocks won’t resume regular trading until Tuesday.
Dario trailed the broader market. The Nasdaq Composite closed Friday at 26,343.97, higher than Monday’s finish at 26,090.73.
DarioHealth’s latest move is the first-quarter numbers out May 13. Revenue hit $5.6 million, up from $5.2 million in Q4, but down from $6.8 million last year, when a major pharma customer booked a one-time item. Operating expenses dropped 21% from a year earlier to $10.5 million, and operating loss came in slimmer at $7.3 million.
Management said the quarter showed the model heading the right way. CEO Erez Raphael told investors Dario entered 2026 with “continued momentum,” and said the “financial trajectory is on track.” CFO Chen Franco-Yehuda put it as “revenue growing, cost declining.” Stock Insights AI
Dario’s short-term picture isn’t only about earnings. The company’s test is turning partner access into sales. President and Chief Commercial Officer Steven Nelson said partners account for over 80% of revenue now, reaching more than 116 million covered lives. Nelson put the commercial pipeline at about $127 million across 241 potential deals.
Dario is moving to sell via employers, health plans and channel partners, not just direct to each customer. The company said B2B2C gross margin held near 80% for the ninth quarter in a row. Gross margin is revenue left after direct costs.
Week ahead looks set to hinge on how buyers read May’s results—progress or not—and whether sellers zero in on funding needs. Management says accounts signed in 2025 will mostly hit recognized revenue in the back half of 2026. The strategic review after unsolicited interest is still in play.
Dario flagged tough competition in its annual filing, listing Teladoc Health, Omada Health, and Virta Health as digital-health rivals in condition management, coaching and virtual care. The company said some of these competitors have bigger sales forces, more funding or have been around longer.
Dario’s May 13 10-Q laid out the risk. The company said its cash wouldn’t cover expected operating costs for the next year from its interim financials, and flagged “substantial doubt” about staying a going concern — shorthand for possible financing needs, cuts, or other changes to survive. First quarter numbers showed $6.0 million in cash burned on operations. SEC
DRIO traded lightly again during the holiday week. The stock faces a straightforward test for now. The company has reduced its spending, pointing to progress with partner channels that it says are scaling up. But investors are still waiting to see if those channels will actually deliver enough cash. If not, the balance sheet becomes the issue.
